Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51
Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80
Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53
Avalyn Pharma To Present Updated Findings From ATLAS Open-Label Extension Trial Highlighting Long-Term Tolerability Profile Of AP01 For Treatment Of Pulmonary Fibrosis, At EULAR 2026
Avalyn To Present Findings From Usability Study For eFlow Nebulizer System At American Thoracic Society 2026 International Conference May 15-20
Avalyn Pharma Shares Open For Trade At $26/Share; IPO Priced At $18/Share On ~16.67M shares
Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
